SEARCH

SEARCH BY CITATION

References

  • 1
    Feldman M. Hemangioma of the liver. Special reference to its association with cysts of the liver and pancreas. Am J Clin Pathol 1958; 29: 160162.
  • 2
    Ishak KG. Mesenchymal tumors of the liver. In: OkudaK, PetersRL, eds. Hepatocellular Carcinoma. New York: Wiley, 1976; 247307.
  • 3
    Adam YG, Huvos AG, Fortner JG. Giant hemangioma of the liver. Ann Surg 1970; 172: 239245.
  • 4
    Berliner L, el Ferzli G, Gianvito L, Worth MH Jr, Lowry J, Redmond P, Silich R. Giant cavernous hemangioma of the liver complicated by abscess and thrombosis. Am J Gastroenterol 1983; 78: 835840.
  • 5
    Sewell JH, Weiss K. Spontaneous rupture of hemangioma of the liver. Arch Surgery 1962; 83: 729733.
  • 6
    Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura. Am J Dis Child 1940; 59: 10631070.
  • 7
    Grieco MB, Miscall BG. Giant hemangiomas of the liver. Surg Gynecol Obstet 1978; 47: 783787.
  • 8
    Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137: 38553860.
  • 9
    Kehrl JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS. Further studies of the role of transforming growth factor β in human B cell function. J Immunol 1989; 143: 18681874.
  • 10
    Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 10371050.
  • 11
    Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, et al. Effect of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of inter -feron responsiveness. J Immunol 1986; 136: 39163920.
  • 12
    Geller RL, Smyth MJ, Strobl SL, Bach FH, Ruscetti FW, Longo DL, Ochoa AC. Generation of lymphokine-activated killer activity in T cells. J Immunol 1991; 146: 32803288.
  • 13
    Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 1993; 92: 25692576.
  • 14
    Johnson CM, Sheedy PF II, Stanson AW, Stephens DH, Hattery RR, Adson MA. Computed tomography and angiography of cavernous hemangiomas of the liver. Radiology 1981; 138: 115121.
  • 15
    Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, et al. Plasma transforming growth factor-β1i in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer 1994; 73: 22752279.
  • 16
    Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A 1980; 77: 34943498.
  • 17
    Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor α in normal human adult kidney and enhanced expression of transforming growth factors α and β in renal cell carcinoma. Cancer Res 1989; 49: 69726975.
  • 18
    Yoshida K, Yokozaki H, Niimoto M, Ito H, Ito M, Tahara E. Expression of TGF-β and procollagen type I and type III in human gastric carcinomas. Int J Cancer 1989; 44: 394398.
  • 19
    Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, et al. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991; 51: 40804083.
  • 20
    Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995; 89: 4548.
  • 21
    Lee G, Ellingsworth LR, Gillis S, Wall R, Kincade PW. Beta transforming growth factors are potential regulators of B lymphopoiesis. J Exp Med 1987; 166: 12901297.
  • 22
    Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, et al. Transforming growth factor type beta (TGF beta) inhibits Gl to S transition, but not activation of human B lymphocytes. Exp Cell Res 1987; 171: 213222.
  • 23
    Bartlett WC, Purchio A, Fell HP, Noelle RJ. Cognate interactions between helper T cells and B cells. VI. TGF-β inhibits B cell activation and antigen-specific, physical interactions between Th and B cells. Lymph Cytokine Res 1991; 10: 177183.
  • 24
    Coffman RL, Lebman DA, Schrader B. Transforming growth factor specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 1989; 170: 10391044.
  • 25
    Kim P-H, Kagnoff MF. Transforming growth factor-β1 increases IgA iso-type switching at the clonal level. J Immunol 1990; 145: 37733778.
  • 26
    Tsunawaki S, Sporn MB, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334: 260262.
  • 27
    Jin B, Scott JL, Vadas MA, Burns GF. TGF-β down-regulates TliSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 1989; 66: 570576.
  • 28
    Li X-F, Takiuchi H, Zou J-P, Katagiri T, Yamamoto N, Nagata T, Ono S, et al. Transforming growth factor-β (TGF-β)-mediated immunosuppres-sion in the tumor-bearing state: enhanced production of TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn J Cancer Res 1993; 84: 315325.
  • 29
    Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA. Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells: comparison of active and latent TGF-β1. J Exp Med 1990; 172: 17771784.
  • 30
    Maede R, Askenase PW, Geba GP, Neddermann K, Jacoby RO, Pasternak RD. Transforming growth factor-β1 inhibits murine immediate and delayed hypersensitivity. J Immunol 1992; 149: 521528.
  • 31
    Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor β: biological function and chemical structure. Science 1986; 233: 532534.
  • 32
    Knabbe C, Lippman ME, Wakefield LM. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417428.
  • 33
    Kositchek RJ, Cullen RA. Hemangiomatosis of the liver with thrombosis following use of an oral contraceptive. California Medicine 1970; 113: 7074.
  • 34
    Morley JE, Myers JB, Sack FS, Kalk F, Epstein EE, Lannon J. Enlargement of cavernous haemangioma associated with exogenous administration of oestrogens. South African Medical Journal 1974; 48: 695697.
  • 35
    Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 41674171.
  • 36
    Yang EY, Moses HL. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111: 731741.